MapLight Therapeutics, Inc. (MPLT) vs REGENXBIO Inc. (RGNX)
A side-by-side comparison of MapLight Therapeutics, Inc. and REGENXBIO Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MPLT
MapLight Therapeutics, Inc.
$9.69HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RGNX
REGENXBIO Inc.
$7.45HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — MPLT vs RGNX
growth of $100 · dividends reinvested · last 1yMPLT -49.4% (-49.4%/yr)RGNX -40.4% (-40.4%/yr)RGNX compounded faster over this window
MPLT RGNX
MPLT vs RGNX: by the numbers
- •MPLT is the larger company ($411M vs $385M market cap).
- •Both run net losses; MPLT's is the smaller (0.00% vs -112.58% net margin).
Metrics side by side
Valuation
| Metric | MPLT | RGNX |
|---|---|---|
| P/S ratio | N/A | 2.21 |
| P/B ratio | 1.18 | 5.37 |
Profitability
| Metric | MPLT | RGNX |
|---|---|---|
| Gross margin | 0.00% | 88.09% |
| Operating margin | 0.00% | -94.08% |
| Net margin | 0.00% | -112.58% |
| ROE | -65.99% | -273.72% |
| ROIC | -69.35% | -54.00% |
Growth (annualized)
| Metric | MPLT | RGNX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.59% |
| Total return CAGR (5Y) | N/A | -24.15% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.